Renaissance Capital logo

Codiak BioSciences Priced, Nasdaq: CDAK

Early stage biotech developing novel exosome therapeutics for cancers.

Industry: Health Care

Latest Trade: $12.75 0.00 (0.0%)

First Day Return: -19.2%

Return from IPO: -15.0%

Industry: Health Care

We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. Exosomes have evolved as intercellular transfer mechanisms for complex, biologically active macromolecules and have emerged in recent years as a compelling potential drug delivery vehicle. There have been no approved exosome-based therapeutics to date. By leveraging our deep understanding of exosome biology, we have developed our engineering and manufacturing platform, or engEx Platform, to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutics. We have utilized our engEx Platform to generate a deep pipeline of engineered exosomes, or engEx exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Our lead product candidates, exoSTING and exoIL-12, are being developed to address solid tumors and we expect to enter clinical trials in the second half of 2020.
more less
IPO News for Codiak BioSciences
more
IPO Data
IPO File Date 09/09/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.5
Deal Size ($mm) $83
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/13/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.5
Deal Size ($mm) $83
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2015
Employees 101
Website www.codiakbio.com